ArticleNature communications2019
Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Characterizing tumor microenvironment heterogeneity in EBVFrontiers in immunology · 2026Article
- Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS.Clinical pharmacology and therapeutics · 2026Article
- GNAQ inhibits tumorigenesis via the ARHGEF25-mediated RHOA pathway in NK/T-cell lymphoma.Cancer biology & therapy · 2025Article
- G Protein-Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers.MedComm · 2025Review
- Case Report: A rare case of bilateral primary Müllerian adenosarcoma of the ovary with Uncommon extensive metastasis andFrontiers in oncology · 2025Article
- LMP1 enhances aerobic glycolysis in natural killer/T cell lymphoma.Cell death & disease · 2024Article
- Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations.Annals of hematology · 2024Article
- Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation.International journal of hematology · 2023Article
- Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting.International journal of molecular sciences · 2023Article
- Contribution of the Epstein-Barr virus to the oncogenesis of mature T-cell lymphoproliferative neoplasms.Frontiers in oncology · 2023Review
- GNAQ T96S mutation abrogates the ability of wild-type GNAQ to induce apoptosis by phosphorylating annexin A2 in natural killer/T cell lymphoma.Cancer science · 2022Article
- Genomic landscape of T-cell lymphoblastic lymphoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2022Article
- Overarching roles of diacylglycerol signaling in cancer development and antitumor immunity.Science signaling · 2022Review
- Misaligned sequencing reads from the GNAQ-pseudogene locus may yield GNAQ artefact variants.Nature communications · 2022Article
- Integrated driver mutations profile of chinese gastrointestinal-natural killer/T-cell lymphoma.Frontiers in oncology · 2022Article
- GNAQ mutations drive port wine birthmark-associated Sturge-Weber syndrome: A review of pathobiology, therapies, and current models.Frontiers in human neuroscience · 2022Review
- Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens.Saudi journal of biological sciences · 2022Article
- Review
- Coexisting and Second Primary Cancers in Patients with Uveal Melanoma: A 10-Year Nationwide Database Analysis.Journal of clinical medicine · 2021Article
- Virus-Driven Carcinogenesis.Cancers · 2021Review
Corrections and comments
- Commented on by
Authors and funding
31 authors at 5 institutions in 2 countries.
Zhaoming Li *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.ORCID http://orcid.org/0000-0002-2876-5182
Xudong Zhang *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Weili Xue *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Yanjie Zhang *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Chaoping LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Yue SongDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Mei MeiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Lisha LuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Yingjun WangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Zhiyuan ZhouDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Mengyuan JinDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Yangyang BianMedical Research Centre, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Lei ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Xinhua WangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Ling LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Xin LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Xiaorui FuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Zhenchang SunDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Jingjing WuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Feifei NanDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Yu ChangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Jiaqin YanDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Hui YuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Xiaoyan FengDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Guannan WangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Dandan ZhangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Xuefei FuNovogene Bioinformatics Technology Co, Ltd, 38 Xueqing Road, 100083, Beijing, China.
Yuan ZhangThe Academy of Medical Science of Zhengzhou University, 450052, Zhengzhou, China.
Ken H YoungDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Wencai LiDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China. wencailizzu@126.com.
Mingzhi ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China. mingzhi_zhang@126.com.
First Affiliated Hospital of Zhengzhou University · CNNovogene Bioinformatics Institute · CNZhengzhou University · CNHenan Energy & Chemical Industry Group (China) · CNThe University of Texas MD Anderson Cancer Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer/T cell lymphoma (NKTCL) is a rare and aggressive malignancy with a higher prevalence in Asia and South America. However, the molecular genetic mechanisms underlying NKTCL remain unclear. Here, we identify somatic mutations of GNAQ (encoding the T96S alteration of Gαq protein) in 8.7% (11/127) of NKTCL patients, through whole-exome/targeted deep sequencing. Using conditional knockout mice (Ncr1-Cre-Gnaq
Indexed as
Mutation, MissenseAnimalsFemaleGTP-Binding Protein alpha Subunits, Gq-G11HumansLymphoma, T-CellMaleMiceMice, Inbred C57BLMice, KnockoutNatural Killer T-CellsGTP-Binding Protein alpha Subunits, Gq-G11
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.